资讯

MPR3 小时
FDA Denies Approval of Brain Cancer Imaging Agent
TLX101-CDx is an investigational positron emission tomography agent that targets the membrane transport proteins, LAT1 and LAT2.
Neurology Advisor7 小时
Pediatric Brain Tumor Risk Increases With CT Radiation Exposure
There is a positive association between exposure to at least 1 head/neck CT scan and the risk for pediatric brain tumors.
Shares Are Expensive With the Market Likely Extrapolating Telix's Current Sales Growth Rates
The solid cash conversion allows Telix to internally fund organic growth and flexibility to pursue acquisitions. We expect the company to reinvest the majority of earnings into R&D. We forecast ...
The Cut on MSN9 小时
Will a CT Scan Give You Cancer?
Radiation from the images causes 5 percent of cancer cases, according to a new study. The doctor who made this grim discovery ...
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study ...
Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm’s commitment to developing ...
Taiwan News14 小时
Taiwan-US team develops non-invasive imaging for brain disorders
A research team at National Sun Yat-sen University has developed a non-invasive imaging technology designed for diagnosing ...
Telix setback in drug approval in US, amid Trump workforce cuts to FDA
Telix CEO Christian Behrenbruch hinted changes to the US Food and Drug Administration have hampered approval of its new brain ...
HotCopper on MSN18 小时
Telix dips as FDA knocks back new drug for imaging rare brain cancer – despite prior approval
Telix (ASX:TLX) has copped a sharp jab on Monday as the FDA says its drug TLX101-CDx, AKA Floretyrosine, can’t be accepted ...